Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6752214rdf:typepubmed:Citationlld:pubmed
pubmed-article:6752214lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:6752214lifeskim:mentionsumls-concept:C0014442lld:lifeskim
pubmed-article:6752214lifeskim:mentionsumls-concept:C0424295lld:lifeskim
pubmed-article:6752214lifeskim:mentionsumls-concept:C0686347lld:lifeskim
pubmed-article:6752214lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:6752214lifeskim:mentionsumls-concept:C1515021lld:lifeskim
pubmed-article:6752214lifeskim:mentionsumls-concept:C0599861lld:lifeskim
pubmed-article:6752214pubmed:issue5lld:pubmed
pubmed-article:6752214pubmed:dateCreated1982-12-18lld:pubmed
pubmed-article:6752214pubmed:abstractTextThis study was undertaken to test a hypothesis that tardive dyskinesia (TD) patients with high plasma dopamine-beta-hydroxylase (DBH) activity would also have other enzymatic alterations suggestive of noradrenergic hyperactivity. Plasma renin activity was chosen as a peripheral indicator of noradrenergic function. We measured plasma renin activity in three groups of female psychiatric inpatients over the age of 50: a TD group with high plasma DBH activity, a TD group with low plasma DBH activity, and a non-TD group. The high-DBH TD group had significantly greater plasma renin activity than the other two groups. Our results are consistent with the hypothesis that a subgroup of TD patients has relative noradrenergic hyperactivity.lld:pubmed
pubmed-article:6752214pubmed:languageenglld:pubmed
pubmed-article:6752214pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6752214pubmed:citationSubsetIMlld:pubmed
pubmed-article:6752214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6752214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6752214pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6752214pubmed:statusMEDLINElld:pubmed
pubmed-article:6752214pubmed:monthOctlld:pubmed
pubmed-article:6752214pubmed:issn0271-0749lld:pubmed
pubmed-article:6752214pubmed:authorpubmed-author:LinnoilaMMlld:pubmed
pubmed-article:6752214pubmed:authorpubmed-author:WyattR JRJlld:pubmed
pubmed-article:6752214pubmed:authorpubmed-author:JesteD VDVlld:pubmed
pubmed-article:6752214pubmed:authorpubmed-author:PhelpsB HBHlld:pubmed
pubmed-article:6752214pubmed:authorpubmed-author:WagnerR LRLlld:pubmed
pubmed-article:6752214pubmed:authorpubmed-author:FordisC MCMlld:pubmed
pubmed-article:6752214pubmed:issnTypePrintlld:pubmed
pubmed-article:6752214pubmed:volume2lld:pubmed
pubmed-article:6752214pubmed:ownerNLMlld:pubmed
pubmed-article:6752214pubmed:authorsCompleteYlld:pubmed
pubmed-article:6752214pubmed:pagination318-20lld:pubmed
pubmed-article:6752214pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:6752214pubmed:meshHeadingpubmed-meshheading:6752214-...lld:pubmed
pubmed-article:6752214pubmed:meshHeadingpubmed-meshheading:6752214-...lld:pubmed
pubmed-article:6752214pubmed:meshHeadingpubmed-meshheading:6752214-...lld:pubmed
pubmed-article:6752214pubmed:meshHeadingpubmed-meshheading:6752214-...lld:pubmed
pubmed-article:6752214pubmed:meshHeadingpubmed-meshheading:6752214-...lld:pubmed
pubmed-article:6752214pubmed:meshHeadingpubmed-meshheading:6752214-...lld:pubmed
pubmed-article:6752214pubmed:meshHeadingpubmed-meshheading:6752214-...lld:pubmed
pubmed-article:6752214pubmed:meshHeadingpubmed-meshheading:6752214-...lld:pubmed
pubmed-article:6752214pubmed:meshHeadingpubmed-meshheading:6752214-...lld:pubmed
pubmed-article:6752214pubmed:year1982lld:pubmed
pubmed-article:6752214pubmed:articleTitleEnzyme studies in tardive dyskinesia. III. Noradrenergic hyperactivity in a subgroup of dyskinetic patients.lld:pubmed
pubmed-article:6752214pubmed:publicationTypeJournal Articlelld:pubmed